Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2024-05-09 Interim / Quarterly Rep…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Form 10-Q-For the quarterly period ended March 31, 2024
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) by Oramed Pharmaceuticals Inc. It explicitly states it is a 'Quarterly Report' for the period ended March 31, 2024, and contains interim condensed consolidated financial statements, management's discussion and analysis, and other required disclosures. This fits the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-09 English
Form 10-Q-For the quarterly period ended March 31, 2024
Report Publication Announcement Classification · 98% confidence The document explicitly states it is an 'Other Report or Announcement' under Israeli regulations and, crucially, mentions that it has 'Attached hereto is a report on *Form 10-Q*'. A Form 10-Q is the standard SEC filing for quarterly financial reports. Since this document is short (1860 chars) and serves to announce the availability of the actual 10-Q report (indicated by the attachment reference and the nature of the filing as an announcement to the ISA/TASE), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. The presence of the 10-Q reference strongly points away from general regulatory filings (RNS) or earnings releases (ER) which are usually less specific about the attached SEC form.
2024-05-09 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2024
2024-05-09 English
Update on the receipt of payments for the Scilex transaction
Regulatory Filings Classification · 95% confidence The document explicitly identifies itself as a "FORM 8-K" and a "CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934". Form 8-K filings are used to announce material, unscheduled events. None of the specific filing codes (10-K, ER, IR, DIV, etc.) perfectly match the general nature of a Form 8-K reporting an 'Other Event' (Item 8.01) regarding a debt payment received. Since Form 8-K is a general current report for material events not covered by other specific periodic reports, and there is no dedicated 'Form 8-K' code, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it covers miscellaneous SEC filings that don't fit the other specialized categories.
2024-05-06 English
Update on the receipt of payments for the Scilex transaction
Report Publication Announcement Classification · 98% confidence The document is a filing notification from Oramed Pharmaceuticals Inc. to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *Form 8-K*'. A Form 8-K is a report of unscheduled material events or corporate changes required by the SEC. Since this document is merely announcing the attachment of an 8-K report and is very short (1863 characters), it fits the criteria for a Report Publication Announcement (RPA) according to Rule 2, rather than being the full 8-K filing itself (which would likely be classified as RNS if it didn't fit another specific category, but RPA is more precise for announcing a report's release).
2024-05-06 English
CURRENT REPORT
Regulatory Filings
2024-05-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.